384 related articles for article (PubMed ID: 21619426)
1. Pharmacogenetics of drug transporters in the enterohepatic circulation.
Stieger B; Meier PJ
Pharmacogenomics; 2011 May; 12(5):611-31. PubMed ID: 21619426
[TBL] [Abstract][Full Text] [Related]
2. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.
Sakaeda T; Nakamura T; Okumura K
Pharmacogenomics; 2003 Jul; 4(4):397-410. PubMed ID: 12831320
[TBL] [Abstract][Full Text] [Related]
4. Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1).
Ishikawa T; Sakurai A; Hirano H; Lezhava A; Sakurai M; Hayashizaki Y
Pharmacol Ther; 2010 Apr; 126(1):69-81. PubMed ID: 20138191
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.
Sakaeda T; Nakamura T; Okumura K
Curr Top Med Chem; 2004; 4(13):1385-98. PubMed ID: 15379652
[TBL] [Abstract][Full Text] [Related]
6. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
[TBL] [Abstract][Full Text] [Related]
7. MDR1 gene polymorphisms and clinical relevance.
Li YH; Wang YH; Li Y; Yang L
Yi Chuan Xue Bao; 2006 Feb; 33(2):93-104. PubMed ID: 16529292
[TBL] [Abstract][Full Text] [Related]
8. [Effect of genetic polymorphism on the activity of drug transporters and its clinical significance].
Zhang HX; Wang LS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 33(8):765-9. PubMed ID: 18772522
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1).
Ishikawa T; Onishi Y; Hirano H; Oosumi K; Nagakura M; Tarui S
Biol Pharm Bull; 2004 Jul; 27(7):939-48. PubMed ID: 15256718
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
Huang Y
Cancer Metastasis Rev; 2007 Mar; 26(1):183-201. PubMed ID: 17323126
[TBL] [Abstract][Full Text] [Related]
11. Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.
Mooij MG; Nies AT; Knibbe CA; Schaeffeler E; Tibboel D; Schwab M; de Wildt SN
Clin Pharmacokinet; 2016 May; 55(5):507-24. PubMed ID: 26410689
[TBL] [Abstract][Full Text] [Related]
12. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.
Perri D; Ito S; Rowsell V; Shear NH
Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.
Cascorbi I
Handb Exp Pharmacol; 2011; (201):261-83. PubMed ID: 21103972
[TBL] [Abstract][Full Text] [Related]
14. Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.
Zhou Q; Yu LS; Zeng S
Drug Metab Rev; 2014 Aug; 46(3):283-90. PubMed ID: 24796860
[TBL] [Abstract][Full Text] [Related]
15. Transporter pharmacogenetics: do we need function? Do we need motion?
Pastor-Anglada M
Pharmacogenomics; 2013 Oct; 14(13):1537-40. PubMed ID: 24088123
[No Abstract] [Full Text] [Related]
16. Pharmaceutical and pharmacological importance of peptide transporters.
Brandsch M; Knütter I; Bosse-Doenecke E
J Pharm Pharmacol; 2008 May; 60(5):543-85. PubMed ID: 18416933
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenetic implications of transmembrane transporters for the uptake, distribution and excretion of drugs].
Gerloff T; Roots I
Dtsch Med Wochenschr; 2003 Nov; 128(46):2431-6. PubMed ID: 14614658
[No Abstract] [Full Text] [Related]
18. ABCB1 pharmacogenetics: progress, pitfalls, and promise.
Chinn LW; Kroetz DL
Clin Pharmacol Ther; 2007 Feb; 81(2):265-9. PubMed ID: 17259950
[TBL] [Abstract][Full Text] [Related]
19. Effect of drug transporter pharmacogenetics on cholestasis.
Dietrich CG; Geier A
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1533-51. PubMed ID: 25260651
[TBL] [Abstract][Full Text] [Related]
20. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
Rodieux F; Gotta V; Pfister M; van den Anker JN
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S173-92. PubMed ID: 27385174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
